Tamitinol in paedopsychiatric out-patient therapy.
A study was carried out in 11 children, ranging in age from 7 to 12 years, to determine the clinical effect of tamitinol, in addition to psychotherapy, in alleviating disturbances of learning and behaviour. Tamitinol was administered as one 100 mg tablet per 10 kg body weight daily for 8 weeks. Assessments were made of the patients' mental condition using a 7-point rating scale, before and during treatment. Global response to treatment and tolerance were evaluated at the end of the trial by the clinician and the patients (or parents). Significant improvement was noted in 7 of the 10 children who completed the study. Six of the 13 psychiatric symptoms evaluated by the clinician were significantly improved (p less than 0.01). The drug was well tolerated by all patients.
D001835:Body Weight / Q000187:drug effects; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007859:Learning Disabilities / Q000188:drug therapy*; D008297:Male; D011725:Pyridines / Q000627:therapeutic use*; D011746:Pyrithioxin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D011725:Pyridines; C016928:tamitinol; D011746:Pyrithioxin